Exclusive Summary

• Zero patent risks with long-expired patents, allowing immediate market entry and commercial distribution globally.
• Listed as a WHO Essential Medicine, targeting the rigid demand of over 300 million global surgeries annually, particularly C-sections and orthopedic procedures.
• Backed by mature sterile injectable manufacturing capabilities, offering stable supply to effectively resolve regional drug shortages.
• Significant cost advantages coupled with comprehensive registration dossiers (CTD), ensuring high profit margins and rapid market launch for local distributors.